Hypoxia regulates Toll‑like receptor‑9 expression and invasive function in human brain cancer cells in vitro

Sandholm,Jouko; Tuomela,Johanna; Kauppila,Joonas H.; Harris,Kevin W.; Graves,David; Selander,Katri S.

doi:10.3892/ol.2014.2095

Hypoxia regulates Toll‑like receptor‑9 expression and invasive function in human brain cancer cells in vitro

Authors:
- Jouko Sandholm
- Johanna Tuomela
- Joonas H. Kauppila
- Kevin W. Harris
- David Graves
- Katri S. Selander
View Affiliations

Affiliations: Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA, Department of Pathology, Oulu University Hospital, Oulu 90029, Finland, Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2095
Pages: 266-274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptor‑9 (TLR9) is a cellular DNA sensor of the innate immune system. TLR9 is widely expressed in a number of tumors, including brain cancer; however, little is known regarding its regulation and involvement in cancer pathophysiology. The present study demonstrated that hypoxia upregulates and downregulates TLR9 expression in human brain cancer cells in vitro, in a cell‑specific manner. In addition, hypoxia‑induced TLR9 upregulation was associated with hypoxia‑induced invasion; however, such invasion was not detected in cells where hypoxia had suppressed TLR9 expression. Furthermore, suppression of TLR9 expression through TLR9 siRNA resulted in an upregulation of matrix metalloproteinase (MMP)‑2, ‑9 and ‑13 and tissue inhibitor of matrix metalloproteinases‑3 (TIMP‑3) mRNA, and a decreased invasion of cells in normoxia, in a cell‑specific manner. In cells where hypoxia induced TLR9 expression, TLR9 expression and invasion were reduced by TLR9 siRNA. The decreased invasion observed in hypoxia was associated with the decreased expression of the MMPs and a concomitant increase in TIMP‑3 expression. In conclusion, hypoxia regulates the invasion of brain cancer cells in vitro in a TLR9‑dependent manner, which is considered to be associated with a complex expression pattern of TLR9‑regulated mediators and inhibitors of invasion.

View Figures

View References

1	Akira S and Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 85:85–95. 2003.
2	Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol. 25:381–386. 2004.
3	Matsumoto M, Funami K, Tanabe M, et al: Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol. 171:3154–3162. 2003.
4	Nishiya T and DeFranco AL: Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem. 279:19008–19017. 2004.
5	Schmausser B, Andrulis M, Endrich S, et al: Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 136:521–526. 2004.
6	Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ and Segal DM: TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol. 173:1179–1183. 2004.
7	Palm NW and Medzhitov R: Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 227:221–233. 2009.
8	Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 295:179–185. 2005.
9	Schaefer TM, Desouza K, Fahey JV, Beagley KW and Wira CR: Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology. 112:428–436. 2004.
10	Bowman CC, Rasley A, Tranguch SL and Marriott I: Cultured astrocytes express toll-like receptors for bacterial products. Glia. 43:281–291. 2003.
11	Platz J, Beisswenger C, Dalpke A, et al: Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol. 173:1219–1223. 2004.
12	Mempel M, Voelcker V, Köllisch G, et al: Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol. 121:1389–1396. 2003.
13	Zaks-Zilberman M, Zaks TZ and Vogel SN: Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 15:156–165. 2001.
14	Ilvesaro JM, Merrell MA, Li L, et al: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res. 6:1534–1543. 2008.
15	Ilvesaro JM, Merrell MA, Swain TM, et al: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 67:774–781. 2007.
16	Merrell MA, Ilvesaro JM, Lehtonen N, et al: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006.
17	Wang C, Cao S, Yan Y, et al: TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer. 10:4152010.
18	Jukkola-Vuorinen A, Rahko E, Vuopala KS, et al: Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun. 1:59–68. 2009.
19	Väisänen MR, Jukkola-Vuorinen A, Vuopala KS, Selander KS and Vaarala MH: Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett. 5:1659–1663. 2013.
20	Väisänen MR, Väisänen T, Jukkola-Vuorinen A, et al: Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 70:817–824. 2010.
21	Berger R, Fiegl H, Goebel G, et al: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101:1059–1066. 2010.
22	Grauer OM, Molling JW, Bennink E, et al: TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol. 181:6720–6729. 2008.
23	Zhao D, Alizadeh D, Zhang L, et al: Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res. 17:771–782. 2011.
24	Ruan K, Song G and Ouyang G: Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 107:1053–1062. 2009.
25	Bar EE: Glioblastoma, cancer stem cells and hypoxia. Brain Pathol. 21:119–129. 2011.
26	Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P and Eltzschig HK: Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One. 2:e13642007.
27	Filippova N, Yang X, King P and Nabors LB: Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function. J Biol Chem. 287:32277–32287. 2012.
28	Filippova N, Yang X, Wang Y, et al: The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 9:648–659. 2011.
29	Sandholm J, Kauppila JH, Pressey C, et al: Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat. 132:411–419. 2012.
30	Merrell M, Suarez-Cuervo C, Harris KW, Väänänen HK and Selander KS: Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat. 81:231–241. 2003.
31	Tuomela J, Sandholm J, Karihtala P, et al: Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 135:481–493. 2012.
32	Kauppila JH, Karttunen TJ, Saarnio J, et al: Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion. APMIS. 121:511–522. 2013.
33	Muñoz-Nájar UM, Neurath KM, Vumbaca F and Claffey KP: Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 25:2379–2392. 2006.
34	Arvelo F and Cotte C: Hypoxia in cancer malignity. Review Invest Clin. 50:529–546. 2009.(In Spanish).
35	Langton KP, Barker MD and McKie N: Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby’s fundus dystrophy mutation. J Biol Chem. 273:16778–16781. 1998.
36	Stricklin GP: Human fibroblast tissue inhibitor of metalloproteinases: glycosylation and function. Coll Relat Res. 6:219–228. 1986.
37	Hemmi H, Takeuchi O, Kawai T, et al: A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745. 2000.
38	Lande R, Gregorio J, Facchinetti V, et al: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 449:564–569. 2007.
39	Meng Y, Kujas M, Marie Y, et al: Expression of TLR9 within human glioblastoma. J Neurooncol. 88:19–25. 2008.
40	Chiang CY, Engel A, Opaluch AM, et al: Cofactors required for TLR7- and TLR9-dependent innate immune responses. Cell Host Microbe. 11:306–318. 2012.
41	Yang L, Lin C, Wang L, Guo H and Wang X: Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 318:2417–2426. 2012.
42	Chen W, Hartman R, Ayer R, et al: Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem. 111:726–736. 2009.
43	Méndez O, Zavadil J, Esencay M, et al: Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer. 9:1332010.
44	Lu DY, Yu WH, Yeh WL, et al: Hypoxia-induced matrix metalloproteinase-13 expression in astrocytes enhances permeability of brain endothelial cells. J Cell Physiol. 220:163–173. 2009.
45	Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G and DeMatteo RP: Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology. 51:621–632. 2010.
46	Rifkin IR, Leadbetter EA, Busconi L, Viglianti G and Marshak-Rothstein A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 204:27–42. 2005.
47	Tuomela J, Grönroos TJ, Valta MP, et al: Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer. 10:5962010.
48	Barcellos-Hoff MH, Newcomb EW, Zagzag D and Narayana A: Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol. 19:163–170. 2009.
49	Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 13:739–749. 2006.
50	Nicholas SA, Oniku AE and Sumbayev VV: Myeloid cell death associated with Toll-like receptor 7/8-mediated inflammatory response. Implication of ASK1, HIF-1 alpha, IL-1 beta and TNF-alpha. Mol Immunol. 48:240–247. 2010.
51	Paone A, Galli R, Gabellini C, et al: Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia. 12:539–549. 2010.
52	Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS and Lee JY: Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology. 129:516–524
53	Sinha S, Koul N, Dixit D, Sharma V and Sen E: IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma. Cell Signal. 23:1869–1875. 2011.